These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 6231092)

  • 1. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
    Legha SS; Ajani JA; Blumenschein GR; Hortobagyi GN; Buzdar AU
    Cancer; 1984 May; 53(9):1836-40. PubMed ID: 6231092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
    Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
    Aboud A; Buzdar AU; Yap HY; Hortobagyi GN; Blumenschein GR
    J Surg Oncol; 1984 Jul; 26(3):205-7. PubMed ID: 6610802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
    Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
    Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.
    Kolarić K; Tomek R
    Tumori; 1990 Oct; 76(5):472-5. PubMed ID: 2256193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
    Kolarić K; Vukas D; Potrebica V
    Tumori; 1989 Apr; 75(2):132-6. PubMed ID: 2741218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report.
    Kolarić K; Vukas D; Roth A; Potrebica V; Cervek J; Cerar O
    Tumori; 1985 Apr; 71(2):159-65. PubMed ID: 3890307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
    Vogel CL; Smalley RV; Raney M; Krauss S; Carpenter J; Velez-Garcia E; Fishkin E; Raab S; Moore MR; Stagg M
    J Clin Oncol; 1984 Jun; 2(6):643-51. PubMed ID: 6374057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin.
    Kennealey GT; Boston B; Mitchell MS; Knobf MK; Bobrow SN; Pezzimenti JF; Lawrence R; Bertino JR
    Cancer; 1978 Jul; 42(1):27-33. PubMed ID: 667798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, adriamycin, and cis-platinum (CAP) in metastatic and locally advanced breast cancer.
    Verusio C; Bajetta E; Ferrari L; Bartoli C; Valagussa P; Bonadonna G
    Am J Clin Oncol; 1988 Aug; 11(4):435-9. PubMed ID: 3407621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
    Hirshaut Y; Kesselheim H
    Cancer; 1983 Jun; 51(11):1998-2004. PubMed ID: 6687698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
    Kolarić K; Roth A; Vukas D; Cervek J
    Cancer Chemother Pharmacol; 1984; 13(2):142-4. PubMed ID: 6380789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
    Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
    Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer.
    Yap HY; Blumenschein GR; Hortobagyi GN; Buzdar AU; Schell FC; Bodey GP
    Am J Clin Oncol; 1982 Oct; 5(5):511-4. PubMed ID: 7180829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.